News Release

15 July 2025

SGX Securities welcomes China Medical System Holdings Limited to Mainboard

SGX Securities today welcomed the secondary listing of China Medical System Holdings Limited on its Mainboard under the stock code "8A8".

China Medical System Holdings Limited (CMS) is a specialty pharmaceutical company with strong presence in China for nearly 30 years. Listed on the Hong Kong Stock Exchange since 2010, CMS has built a differentiated portfolio across key therapeutic areas including cardio-cerebrovascular, central nervous system, gastroenterology, dermatology and ophthalmology.

Lam Kong, Founder, Chairman, Chief Executive and President, China Medical System Holdings Limited, said, "Today marks another significant milestone in CMS's development history. Our listing in Singapore further enhances our presence in the international capital markets. At the same time, by leveraging Singapore's strengths as a hub for global innovation and multinational headquarters, we are advancing our pharmaceutical industry internationalisation strategy, accelerating the construction of the full pharmaceutical value chain of R&D, manufacturing and commercialisation, and working hand-in-hand with our partners to promote the growth of the pharmaceutical industry in emerging markets and deliver meaningful benefits to patients worldwide."

Pol de Win, Head of Global Sales and Origination, SGX Group, said, "We are delighted to welcome China Medical System Holdings Limited to SGX. As a leading player in the healthcare sector, its listing reflects the rising demand for healthcare innovation and access across Asia. As the company looks to expand in Southeast Asia, its listing on SGX offers a strategic springboard, connecting it to international investors and reinforcing Singapore's role as a hub for capital and growth."

With a market capitalisation of approximately HK$28.64 billion (approximately S$4.67 billion) as at the Latest Practicable Date[1], CMS joins SGX's family as the 40th listing in the healthcare sector. China Medical System Holdings Limited opened at S$2.05 today.

-End-

[1] 16 June 2025, being the latest practicable date prior to the issue of China Medical System Holdings Limited's Introductory Document

Singapore Exchange Limited
Company Reg No. 199904940D

2 Shenton Way, #02-02 SGX Centre 1, Singapore 068804
main: +65 6236 8888 fax: +65 6535 6994

sgx.com

About China Medical System Holdings Limited

China Medical System Holdings Limited ("CMS" or the "Group") is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialisation of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. The Group deeply engages in several specialty therapeutic fields, and has developed proven commercialisation capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. The Group continues to advance the in-depth development of its advantageous specialty therapeutic fields to strengthen its competitiveness in cardio-cerebrovascular, gastroenterology, ophthalmology, and skin health businesses, among other specialty fields (with the skin health business having become a leading player in its segment), thereby achieving specialty scale and efficiency.

CMS actively advances its "Industrial Internationalisation" strategy, with Singapore as its regional headquarters for its Southeast Asia and Middle East business. The Group has set up companies in Singapore covering the entire pharmaceutical value chain of R&D, manufacturing, commercialisation and investment, working together to provide local patients with greater access to high-quality and affordable treatment options, and contributing to the development of the pharmaceutical industry chain across the entire Asia-Pacific region.

About Singapore Exchange (SGX Group)

SGX Group seeks to serve as the world's most trusted and efficient international marketplace, operating equity, fixed income, currency and commodity markets to the highest regulatory standards. As one ecosystem with global relevance and influence, we offer multiple growth avenues to our stakeholders through listing, trading, clearing, settlement, depository, data and index services. We are committed to lead on climate action by developing a world-class transition financing and trading hub through SGX FIRST (Future in Reshaping Sustainability Together), our multi-asset sustainability platform. Headquartered in AAA-rated Singapore, we are globally recognised for our risk-management and clearing capabilities. Find out more at www.sgxgroup.com.

About SGX Securities

SGX Securities is Asia's most international marketplace for companies and investors seeking long-term sustainable growth. Our world-class market infrastructure, global connectivity and expansive suite of products offer diverse opportunities for investors to trade and invest with confidence. With about 40% of our listed companies originating outside of Singapore, we are the listing venue of choice, providing a solid foundation for issuers to achieve their business goals. For more information, visit www.sgx.com/securities.

Media Contact

Charissa He
Marketing & Communications
charissa.he@sgx.com
+65 9128 6504